Skip to main content
PMC home page
Journal of Translational Medicine logoLink to Journal of Translational Medicine
. 2006 Sep 4;4:38. doi: 10.1186/1479-5876-4-38

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer

Mads Hald Andersen 1,✉, Rikke B Soerensen 1, Jürgen C Becker 2, Per thor Straten 1
PMCID: PMC1564416  PMID: 16948867

Abstract

Recently, it was described that an HLA-A24 restricted peptide derived from the survivin splice variant survivin-2B can be recognized by CD8(+) cytotoxic T-cells. The identification of an HLA-A24 epitope is critical for survivin-based immunotherapy as HLA-24 is the most frequent HLA allele in Asia. Consequently, this survivin-2B epitope is already a target in a clinical study in patients with advanced or recurrent colorectal cancer expressing survivin. However, the splice variant survivin-2B has been described to be pro-apoptotic, and is only expressed at low levels in most malignant tissues. Furthermore, survivin-2B expression are significantly decreased in later tumor stages and inversely correlated with tumor differentiation and invasion. Consequently, survivin is a more general vaccination candidate than the splice variant survivin-2B. Here, we on the basis of spontaneous immune responses in HLA-A24+ cancer patients describes that a HLA-A24-restricted survivin epitopes does indeed exist. Consequently, this epitope is an attractive target for the ongoing survivin-based peptide immunotherapy against cancer.

Background

The group of Sato recently attempted to identify a HLA-A24-restricted epitope derived from the universal tumor antigen survivin. Although unsuccessful, they reported that an HLA-A24 restricted peptide (AYACNTSTL) derived from the survivin splice variant survivin-2B can be recognized by CD8(+) cytotoxic T-cells [1,2]. Subsequently, as described in this journal this survivin-2B epitope is the target in a phase I clinical study assessing the efficacy of survivin-2B peptide vaccination in patients with advanced or recurrent colorectal cancer expressing survivin [3].

As HLA-A24 is a very frequent allele expressed especially in the Asian population a survivin-derived HLA-A24 restricted epitope would be highly interesting in peptide based immunotherapy against cancer. Survivin is an apoptotic inhibitor that is expressed at high levels in a variety of malignancies. At present, four splicing variants are known for survivin (Survivin, Survivin-2B, Survivin-deltaEx3, Survivin-3B, and survivin-2α) [4-6]. Survivin is over-expressed in almost all cancers including lung, colon, breast, pancreas, stomach, liver, ovaries, and prostate cancer, as well as melanoma, and hematopoetic malignancies [7-9]. Data from a large analysis of human transcripts revealed survivin as the fourth most highly expressed protein in human cancer tissue compared to normal tissue [10]. In contrast, the expression and function in human cancer of the splice variant the survivin-2B is more indistinct. Thus, most studies describe survivin 2-B as to be pro-apoptotic, and only to be expressed at low levels in most malignant tissues [11]. Furthermore, survivin-2B expression are significantly decreased in later tumor stages and inversely correlated with tumor differentiation and invasion [4,11]. Likewise, Islam et al (2000) reported that the expression of survivin-2B is predominant in some neuroblastoma with a good prognosis [12], indicating a possible unfavourable role of survivin-2B in cancer development [13]. In contrast, two recent papers show that high expression of survivin-2B variant is correlated with poor prognosis in cancer patients [14,15]. However, as survivin-2B is not expressed in many malignancies, survivin is a more attractive candidate as a general vaccination candidate than the splice variant survivin-2B. In the present manuscript, we identified an HLA-A24 restricted epitope derived from the universal tumor antigen survivin.

Materials and methods

Patients

Peripheral blood lymphocytes (PBL) from HLA-A24 positive cancer patients were obtained from the University Hospital in Herlev, Denmark. The PBL were isolated using Lymphoprep separation and cryopreserved in FCS with 10% DMSO. Tissue typing was conducted at the Department of Clinical Immunology, The State Hospital, Copenhagen, Denmark. Informed consent was obtained from the patients before any of theses measures.

Interferon-γ and perforin ELISPOT

The interferon-γ and Perforin ELISPOT assays was used to quantify peptide epitope-specific interferon-γ and perforin releasing effector cells, respectively as described previously [16,17]. Briefly, nitrocellulosebottomed 96-well plates (MultiScreen MAIP N45; Millipore) were coated with 7.5 μg/ml capture anti-human interferon-γ (Pf-80/164, Mabtech, Sweden) or 30 μg/ml coating anti-human perforin (Pf-80/164, Mabtech) in 100 μl sterile PBS per well. The wells were washed and T2-A24 cells (a kind from Yasuto Akiyama, Tokyo) and effector cells were added with or without 10 μM peptide. In some assays isolated, CD8 positive T-cells were used as effector cells using CD8+ MACS microbeads (Miltenyi Biotec GmbH, Gladbach, Germany). After incubation (37°C/5%CO2) medium was discarded and the wells were washed prior to addition of the secondary detection Ab, anti-human biotinylated interferon-γ (Mabtech) at 2 μg/ml in 75 μl PSB/BSA per well or anti-human biotinylated perforin (Pf-344-biotin, Mabtech) at 1 μg/ml in 100 μl PSB, respectively. The plates were incubated at RT for 2 h, washed, and 100 μl of streptavidin-ALP (Mabtech) diluted 1:1000 in PBS, was added to each well and the plates were incubated for one hour at RT and the enzyme substrate NBT/BCIP (Invitrogen Life Technologies) was added to each well. Upon appearance of dark spots, the reaction was terminated by washing with tap water. The spots were counted using the ImmunoSpot Series 2.0 Analyzer (CTL Analyzers).

Results and discussion

Recently, a library of overlapping nonamers spanning the length of the survivin protein was used to screen for peptides capable of binding to different HLA alleles, including HLA-A*2402 revealing that the peptides Sur20–28 (STFKNWPFL), Sur96–104 (LTLGEFLKL), Sur133–141 (RAIEQLAAM), Sur126–135 (ETAKKVRRAI) bind to HLA-A24 [18]. These peptides were not included in the study from Sato and colleagues. Subsequently, we scrutinized PBL from HLA-A24+ cancer patients of different origin by means of ELISPOT against these peptides as described [19]. Indeed, strong and frequent CTL responses were detected against Sur20–28 (STFKNWPFL) in cancer patients of different origin as exemplified in figure 1a; an HLA-A24+ renal cancer patient and an HLA-A24+ breast cancer patient hosting strong spontaneous responses against Sur20–28. We were able to detect a response against Sur20–28 in three out of five examined cancer patients (figure 1). The IFN-γ ELISPOT assay is one of the most useful techniques for immunological monitoring of CTL responses and has gained increased application as a measure of specific T cell activation. Previously, we and others have identified CTL epitopes from e.g. survivin, Bcl-2, tyrosinase, CEA, EpCam and Mage on the basis of spontaneous T-cell responses in PBL from cancer patients as presented here [19-25]. However, the IFN-γ ELISPOT does not assess cell-mediated cytotoxicity directly as IFN-γ secretion is not limited to only cytolytic CD8 T-cells cells. Thus, although it has been shown that IFN-γ ELISPOT reactivity in most cases correlates with the capacity to exhibit cytotoxic function, the formal prove for this notion can only be obtained directly. Perforin is a key mediator of target cell death and the perforin ELISPOT assay was recently demonstrated to provide an estimation of cytotoxic effector cell frequency [17]. To insure that the ELISPOT positive cells were indeed CD8+ T-cells, we first isolated CD8+ cells from PBL from eight cancer patients. Subsequently, we analyzed these CD8+ cells both by IFN-γ and perforin ELISPOT (figure 2). In six out of eight patients we were able to detect not only an INF-γ response but in addition a perforin response. Furthermore, the CD8 isolated cells from the eight patients were tested against the irrelevant, HLA-A24-restricted epitope from HIV-1 gag gp4167–75 (RYLKDQQLL) [26]. Data from these experiments showed highly comparable results when testing unpulsed T2-A24 cells vs. T2-A24 cells pulsed with HIV-1 gag gp4167–75, even after a 10 day stimulation of the CD8+ cells with the HIV-1 gag gp4167–75 peptide (data not shown).

Figure 1.

Figure 1

Open in a new tab

HLA-A24 restricted T-cell responses against Sur20–28 in cancer patients. A: Example of the ELISPOT plate performed with the strong responding renal cancer patient R1. B: Spontaneous T cell responses against Sur20–28 as measured by the ELISPOT assay. The average number of peptide specific IFNγ spots formed in response to Sur20–28 among 3 × 105 in vitro stimulated PBL from four breast cancer patients (b1, b2, b3, b4), and 1 renal cancer patient (R1). Non-specific IFNγ spots are subtracted.

Figure 2.

Figure 2

Open in a new tab

Detection of HLA-A24 restricted, sur20–28 specific, CD8 postitive cells by interferon-γ and perforin. ELISPOT. CD8+ cells were isolated from PBL from two HLA-A24+ breast cancer patients (c24, c29), two HLA-A24+ melanoma patients (m3, m6), and four HLA-A24+ renal cancer patients (u1, u8, u13, u15). Spontaneous T-cell responses against Sur20–28 was measured by both interferon-γ and perforin ELISPOT for all patients. The average number of peptide specific IFNγ or perforin spots formed in response to Sur20–28 among 105 in vitro stimulated CD8+ cells. Non-specific spots are subtracted.

Thus, the Sur20–28 reacting cells in the patients PBL are indeed cytotoxic, CD8+ effector cells. Consequently, Sur20–28 is a very attractive target to be included in the ongoing survivin-based peptide immunotherapy against cancer.

Contributor Information

Mads Hald Andersen, Email: mha@cancer.dk.

Rikke B Soerensen, Email: rbs@cancer.dk.

Jürgen C Becker, Email: Becker_JC@klinik.uni-wuerzburg.de.

Per thor Straten, Email: ps@cancer.dk.

References

  1. Hirohashi Y, Torigoe T, Maeda A, Nabeta Y, Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N, Sato N. An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin. Clin Cancer Res. 2002;8:1731–1739. [PubMed] [Google Scholar]
  2. Idenoue S, Hirohashi Y, Torigoe T, Sato Y, Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, Kanaseki T, Ikeda H, Kashiwagi K, Okazaki M, Sasaki K, Sato T, Ohmura T, Hata F, Yamaguchi K, Hirata K, Sato N. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res. 2005;11:1474–1482. doi: 10.1158/1078-0432.CCR-03-0817. [DOI] [PubMed] [Google Scholar]
  3. Tsuruma T, Hata F, Torigoe T, Furuhata T, Idenoue S, Kurotaki T, Yamamoto M, Yagihashi A, Ohmura T, Yamaguchi K, Katsuramaki T, Yasoshima T, Sasaki K, Mizushima Y, Minamida H, Kimura H, Akiyama M, Hirohashi Y, Asanuma H, Tamura Y, Shimozawa K, Sato N, Hirata K. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med. 2004;2:19. doi: 10.1186/1479-5876-2-19. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59:6097–6102. [PubMed] [Google Scholar]
  5. Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun. 2004;314:902–907. doi: 10.1016/j.bbrc.2003.12.178. [DOI] [PubMed] [Google Scholar]
  6. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005;4:11. doi: 10.1186/1476-4598-4-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182. doi: 10.1074/jbc.273.18.11177. [DOI] [PubMed] [Google Scholar]
  8. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, Dombret H, Reyes F, Diebold J, Gisselbrecht C, Salles G, Altieri DC, Molina TJ. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925. [PubMed] [Google Scholar]
  9. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113:1076–1081. doi: 10.1046/j.1523-1747.1999.00776.x. [DOI] [PubMed] [Google Scholar]
  10. Velculescu VE, Madden SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hiraldo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW, . Analysis of human transcriptomes. Nat Genet. 1999;23:387–388. doi: 10.1038/70487. [DOI] [PubMed] [Google Scholar]
  11. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer. 2005;92:212–216. doi: 10.1038/sj.bjc.6602340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Islam A, Kageyama H, Takada N, Kawamoto T, Takayasu H, Isogai E, Ohira M, Hashizume K, Kobayashi H, Kaneko Y, Nakagawara A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19:617–623. doi: 10.1038/sj.onc.1203358. [DOI] [PubMed] [Google Scholar]
  13. Meng H, Lu C, Mabuchi H, Tanigawa N. Prognostic significance and different properties of survivin splicing variants in gastric cancer. Cancer Lett. 2004;216:147–155. doi: 10.1016/j.canlet.2003.12.020. [DOI] [PubMed] [Google Scholar]
  14. Taubert H, Kappler M, Bache M, Bartel F, Kohler T, Lautenschlager C, Blumke K, Wurl P, Schmidt H, Meye A, Hauptmann S. Elevated expression of survivin-splice variants predicts a poor outcome for soft-tissue sarcomas patients. Oncogene. 2005;24:5258–5261. doi: 10.1038/sj.onc.1208702. [DOI] [PubMed] [Google Scholar]
  15. Wagner M, Schmelz K, Wuchter C, Ludwig WD, Dorken B, Tamm I. In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia. Int J Cancer. 2006;119:1291–1297. doi: 10.1002/ijc.21995. [DOI] [PubMed] [Google Scholar]
  16. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61:5964–5968. [PubMed] [Google Scholar]
  17. Zuber B, Levitsky V, Jonsson G, Paulie S, Samarina A, Grundstrom S, Metkar S, Norell H, Callender GG, Froelich C, Ahlborg N. Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells. J Immunol Methods. 2005;302:13–25. doi: 10.1016/j.jim.2005.04.015. [DOI] [PubMed] [Google Scholar]
  18. Bachinsky MM, Guillen DE, Patel SR, Singleton J, Chen C, Soltis DA, Tussey LG. Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun. 2005;5:6.:6. [PubMed] [Google Scholar]
  19. Andersen MH, Pedersen LO, Becker JC, thor Straten P. Identification of a Cytotoxic T Lymphocyte Response to the Apoptose Inhibitor Protein Survivin in Cancer Patients. Cancer Res. 2001;61:869–872. [PubMed] [Google Scholar]
  20. Andersen MH, Reker S, Becker JC, thor Straten P. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol. 2004;122:392–399. doi: 10.1046/j.0022-202X.2004.22242.x. [DOI] [PubMed] [Google Scholar]
  21. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, Thor SP. Immunogenicity of Bcl-2 in cancer patients. Blood. 2005;15:728–734. doi: 10.1182/blood-2004-07-2548. [DOI] [PubMed] [Google Scholar]
  22. Scheibenbogen C, Sun Y, Keilholz U, Song M, Stevanovic S, Asemissen AM, Nagorsen D, Thiel E, Rammensee HG, Schadendorf D. Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer. 2002;20;98:409–414. doi: 10.1002/ijc.10205. [DOI] [PubMed] [Google Scholar]
  23. Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 1996;191:131–142. doi: 10.1016/0022-1759(96)00007-5. [DOI] [PubMed] [Google Scholar]
  24. Nagorsen D, Keilholz U, Rivoltini L, Schmittel A, Letsch A, Asemissen AM, Berger G, Buhr HJ, Thiel E, Scheibenbogen C. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer. Cancer Res. 2000;60:4850–4854. [PubMed] [Google Scholar]
  25. Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Lienard D, Guillaume P, Romero P, Cerottini JC, Rimoldi D. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res. 2001;61:509–512. [PubMed] [Google Scholar]
  26. Ikeda-Moore Y, Tomiyama H, Miwa K, Oka S, Iwamoto A, Kaneko Y, Takiguchi M. Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1. J Immunol. 1997;159:6242–6252. [PubMed] [Google Scholar]

Articles from Journal of Translational Medicine are provided here courtesy of BMC

RESOURCES